

[Cyclophosphamide](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01AA01](#)

EMLc

Indication

Ewing sarcoma of bone and articular cartilage of unspecified sites ICD11 code: [2C22.Z](#)

INN

Cyclophosphamide

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg ; 50 mg

EML status history

First added in 1977 ([TRS 615](#))

Changed in 2015 ([TRS 994](#))

Changed in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Cyclophosphamide](#)

DrugBank

[Cyclophosphamide](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for oral dosage forms of cyclophosphamide on the EML and EMLc be amended to replace 'tablet' with 'solid oral dosage form' to reflect the availability also of capsules and allow greater flexibility in procurement.